688247 宣泰医药
已收盘 03-24 15:00:00
资讯
新帖
简况
宣泰医药：3月23日高级管理人员李方立增持股份合计3747股
证券之星 · 03-23 20:01
宣泰医药：3月23日高级管理人员李方立增持股份合计3747股
宣泰医药(688247.SH)：宣泰®番茄红葡萄籽提取物片获得国产保健食品注册证书
智通财经 · 03-17
宣泰医药(688247.SH)：宣泰®番茄红葡萄籽提取物片获得国产保健食品注册证书
宣泰医药（688247）披露2026年第一次临时股东会通知，3月16日股价上涨1.34%
证券之星 · 03-16
宣泰医药（688247）披露2026年第一次临时股东会通知，3月16日股价上涨1.34%
宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准
智通财经 · 03-13
宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准
每周股票复盘：宣泰医药（688247）维生素K1片获美FDA批准
证券之星 · 03-08
每周股票复盘：宣泰医药（688247）维生素K1片获美FDA批准
宣泰医药：3月4日高管李方立增持股份合计2100股
证券之星 · 03-05
宣泰医药：3月4日高管李方立增持股份合计2100股
宣泰医药(688247.SH)：维生素K1片获得美国FDA批准
智通财经 · 03-02
宣泰医药(688247.SH)：维生素K1片获得美国FDA批准
宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%
智通财经 · 02-27
宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%
宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购
智通财经网 · 02-10
宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购
宣泰医药(688247.SH)：Finer拟减持不超2%股份
智通财经 · 02-09
宣泰医药(688247.SH)：Finer拟减持不超2%股份
宣泰医药（688247）披露2025年年度业绩预告，1月29日股价下跌1.24%
证券之星 · 01-29
宣泰医药（688247）披露2025年年度业绩预告，1月29日股价下跌1.24%
宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%
智通财经 · 01-29
宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%
每周股票复盘：宣泰医药（688247）注射用硫酸艾沙康唑获批上市
证券之星 · 01-11
每周股票复盘：宣泰医药（688247）注射用硫酸艾沙康唑获批上市
宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准
智通财经 · 01-06
宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准
宣泰医药(688247.SH)拟推2025年限制性股票激励计划
智通财经 · 2025-12-25
宣泰医药(688247.SH)拟推2025年限制性股票激励计划
宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%
证券之星 · 2025-12-12
宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%
宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%
证券之星 · 2025-12-08
宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%
11月26日宣泰医药现346.5万元大宗交易
证券之星 · 2025-11-26
11月26日宣泰医药现346.5万元大宗交易
每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%
证券之星 · 2025-11-09
每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%
11月4日宣泰医药发布公告，股东减持8.7万股
证券之星 · 2025-11-04
11月4日宣泰医药发布公告，股东减持8.7万股
加载更多
公司概况
公司名称：
上海宣泰医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-25
主营业务：
上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、美沙拉秦肠溶缓释片、马昔腾坦片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。
发行价格：
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":9.18,"timestamp":1774335600000,"preClose":8.87,"halted":0,"volume":1754435,"delay":0,"changeRate":0.0349,"floatShares":453000000,"shares":453000000,"eps":0.2175,"marketStatus":"已收盘","change":0.31,"latestTime":"03-24 15:00:00","open":9.02,"high":9.18,"low":8.99,"amount":15912100,"amplitude":0.0214,"askPrice":9.19,"askSize":75,"bidPrice":9.18,"bidSize":26,"shortable":0,"etf":0,"ttmEps":0.2175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"adjPreClose":8.87,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":9.76,"lowLimit":7.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":3.18,"roa":"--","peRate":42.206897,"roe":"4.9%","epsLYR":0.28,"committee":-0.005249,"marketValue":4162000000,"turnoverRate":0.0039,"status":0,"afterMarket":{"amount":0,"volume":0,"close":9.18,"buyVolume":0,"sellVolume":0,"time":1774337637558,"indexStatus":"已收盘 03-24 15:30:00","preClose":8.87},"floatMarketCap":4162000000},"requestUrl":"/m/hq/s/688247","defaultTab":"news","newsList":[{"id":"2621033557","title":"宣泰医药：3月23日高级管理人员李方立增持股份合计3747股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621033557","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621033557?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:01","pubTimestamp":1774267282,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月23日市场公开信息、上市公司公告及交易所披露数据整理，宣泰医药最新董监高及相关人员股份变动情况：2026年3月23日公司高级管理人员李方立共增持公司股份3747.0股，占公司总股本为0.0008%。宣泰医药近半年内的董监高及核心技术人员增减持详情如下：宣泰医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入300.28万，融资余额增加；融券净流入1200.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300034950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2620844164","title":"宣泰医药(688247.SH)：宣泰®番茄红葡萄籽提取物片获得国产保健食品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620844164","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620844164?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:41","pubTimestamp":1773733281,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 宣泰医药(688247.SH)发布公告，近日，公司收到国家市场监督管理总局核准签发的《国产保健食品注册证书》，公司产品宣泰®番茄红葡萄籽提取物片获得批准注册。本次宣泰®番茄红葡萄籽提取物片获得《国产保健食品注册证书》，符合公司延伸至大健康领域的战略规划，有利于进一步丰富公司的产品线，提升公司在保健食品领域的竞争力，对公司未来的经营业绩产生积极的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2619456457","title":"宣泰医药（688247）披露2026年第一次临时股东会通知，3月16日股价上涨1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619456457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619456457?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:25","pubTimestamp":1773653130,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，宣泰医药报收于9.85元，较前一交易日上涨1.34%，最新总市值为44.65亿元。该股当日开盘9.83元，最高9.86元，最低9.73元，成交额达1717.93万元，换手率为0.39%。近日，上海宣泰医药科技股份有限公司发布《关于召开2026年第一次临时股东会的通知》。公告显示，公司将于2026年4月1日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合方式，股权登记日为2026年3月25日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600024112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2619195077","title":"宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195077","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619195077?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:32","pubTimestamp":1773397933,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司参与合作开发的恩扎卢胺片收到国家药品监督管理局核准签发的《药品注册证书》，批准恩扎卢胺片上市。恩扎卢胺片是一种雄激素受体抑制剂，本次获批的适应症为：适用于“转移性激素敏感性前列腺癌(mHSPC)成年患者;有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)成年患者;雄激素剥夺治疗(ADT)失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌(CRPC)成年患者的治疗”。此外，该产品已于2025年6月获得美国食品药品监督管理局暂时批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2617663872","title":"每周股票复盘：宣泰医药（688247）维生素K1片获美FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663872?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:02","pubTimestamp":1772910135,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，宣泰医药报收于9.74元，较上周的10.28元下跌5.25%。本周，宣泰医药3月2日盘中最高价报10.12元。本周关注点公司公告汇总：宣泰医药维生素K1片获美国FDA批准，具备美国市场销售资格。股本股东变化高管增减持2026年3月4日，公司高级管理人员李方立增持宣泰医药股份2100.0股，占公司总股本0.0005%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2617412375","title":"宣泰医药：3月4日高管李方立增持股份合计2100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617412375","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617412375?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:01","pubTimestamp":1772712109,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月5日市场公开信息、上市公司公告及交易所披露数据整理，宣泰医药最新董监高及相关人员股份变动情况：2026年3月4日公司高级管理人员李方立共增持公司股份2100.0股，占公司总股本为0.0005%。宣泰医药近半年内的董监高及核心技术人员增减持详情如下：宣泰医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入173.04万，融资余额增加；融券净流入1.56万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500035239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2616389979","title":"宣泰医药(688247.SH)：维生素K1片获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616389979","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616389979?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:08","pubTimestamp":1772438890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司收到美国食品药品监督管理局(以下简称“美国FDA”)的通知，公司向美国FDA申报的维生素K1片的简略新药申请(以下简称“ANDA”，即美国仿制药申请)获得正式批准。本次维生素K1片获得美国FDA批准，标志着具备了在美国市场销售该产品的资格，将有利于公司未来不断扩大在美国市场的销售规模，丰富产品梯队，对公司的长期经营产生积极的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：维生素K1片获得美国FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2614833523","title":"宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833523","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614833523?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:59","pubTimestamp":1772182751,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药 发布2025年度业绩快报，报告期，公司实现营业总收入44,649.88万元，同比下降12.73%;归属于母公司所有者的净利润为4894.63万元，同比下降61.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2610611679","title":"宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610611679","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610611679?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:35","pubTimestamp":1770708905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药 发布公告，近日，公司参与了国家组织集采第1-8批协议期满品种接续采购的申报，根据国家组织集采药品协议期满品种接续采购办公室于2026年2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结果表》显示，公司产品熊去氧胆酸胶囊拟中选本次接续采购。本次第1-8批协议期满品种接续采购，采购周期中，医疗机构将优先使用中标药品，并确保完成约定采购量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2610341546","title":"宣泰医药(688247.SH)：Finer拟减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610341546","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610341546?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:18","pubTimestamp":1770635926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，公司股东Finer Pharma Inc.(简称“Finer”)计划根据市场情况拟通过集中竞价或大宗交易的方式减持其所持有的公司股份数量合计不超过906.68万股，拟减持股份数量占公司总股本的比例不超过2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2607707044","title":"宣泰医药（688247）披露2025年年度业绩预告，1月29日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607707044","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607707044?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:40","pubTimestamp":1769679603,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，宣泰医药报收于10.37元，较前一交易日下跌1.24%，最新总市值为47.01亿元。该股当日开盘10.55元，最高10.56元，最低10.3元，成交额达3450.28万元，换手率为0.73%。近日，上海宣泰医药科技股份有限公司披露《2025年年度业绩预告》。公告显示，公司预计2025年年度实现营业收入39,383.00万元至47,260.00万元，同比减少7.63%至23.02%；归属于母公司所有者的净利润为4,507.00万元至5,408.00万元，同比减少57.65%至64.71%；扣除非经常性损益的净利润为2,961.00万元至3,553.00万元，同比下降68.82%至74.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900030024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2607707808","title":"宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607707808","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607707808?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:26","pubTimestamp":1769678806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润4507万元至5408万元，与上年同期相比，将减少7,362.06万元至8,263.06万元，同比下降57.65%至64.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2602536749","title":"每周股票复盘：宣泰医药（688247）注射用硫酸艾沙康唑获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536749","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536749?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:23","pubTimestamp":1768076586,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，宣泰医药报收于10.29元，较上周的9.7元上涨6.08%。本周，宣泰医药1月9日盘中最高价报10.31元。该药品适用于治疗成人侵袭性曲霉病和侵袭性毛霉病，注册分类为化学药品4类，上市许可持有人为公司本身。原研产品由辉瑞开发，已于2022年6月在国内获批并纳入医保乙类目录。2024年全年及2025年上半年销售额分别为2.04亿元和1.72亿元。此次获批有助于丰富公司产品线，提升竞争力，但销售情况受市场环境等因素影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2601586480","title":"宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601586480","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601586480?lang=zh_cn&edition=full","pubTime":"2026-01-06 15:34","pubTimestamp":1767684853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司收到国家药品监督管理局(简称“国家药监局”)核准签发的《药品注册证书》，批准公司注射用硫酸艾沙康唑上市。注射用硫酸艾沙康唑适用于治疗成人患者下列感染：侵袭性曲霉病，侵袭性毛霉病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2594711231","title":"宣泰医药(688247.SH)拟推2025年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2594711231","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594711231?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:01","pubTimestamp":1766664079,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布2025年限制性股票激励计划(草案)，拟向激励对象授予不超过623万股，约占激励计划草案公告时公司股本总额的1.37%。其中，首次授予不超过498.80万股，首次授予的激励对象不超过64人，授予价格为5.71元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2590502931","title":"宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502931","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590502931?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:30","pubTimestamp":1765549854,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，宣泰医药报收于10.0元，较前一交易日下跌0.5%，最新总市值为45.33亿元。该股当日开盘10.12元，最高10.12元，最低9.98元，成交额达1858.94万元，换手率为0.41%。近日，上海宣泰医药科技股份有限公司发布公告称，公司于2025年12月12日召开董事会，审议通过《关于募投项目延期的议案》，决定将“高端仿制药和改良型新药研发项目”达到预定可使用状态的时间由2025年12月延期至2027年12月。保荐机构对本次延期无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200042008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2589117359","title":"宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589117359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589117359?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:24","pubTimestamp":1765203880,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，宣泰医药报收于10.37元，较前一交易日上涨0.39%，最新总市值为47.01亿元。该股当日开盘10.36元，最高10.4元，最低10.3元，成交额达1844.61万元，换手率为0.39%。近日，上海宣泰医药科技股份有限公司发布公告，其产品西格列汀二甲双胍缓释片以国谈续约形式纳入《国家基本医疗保险、生育保险和工伤保险药品目录》，医保支付标准维持3.47元/片不变，协议有效期为2026年1月1日至2027年12月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2586258562","title":"11月26日宣泰医药现346.5万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2586258562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586258562?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:52","pubTimestamp":1764150766,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日宣泰医药发生大宗交易，交易数据如下：大宗交易成交价格10.5元，成交33万股，成交金额346.5万元，买方营业部为民生证券股份有限公司苏州分公司，卖方营业部为广发证券股份有限公司总部。近三个月该股共发生1笔大宗交易，合计成交3300.0手。该股在过去半年内已有共计3.11亿股限售解禁股上市，占公司总股本的68.61%。截至2025年11月26日收盘，宣泰医药报收于10.5元，上涨0.19%，换手率1.08%，成交量4.88万手，成交额5200.03万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600027282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2582554864","title":"每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582554864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582554864?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:54","pubTimestamp":1762635250,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，宣泰医药报收于10.73元，较上周的10.98元下跌2.28%。期间股价下跌0.09%，截至11月4日收盘价为10.86元。原减持计划拟减持不超过700万股，实际减持321.8万股，计划已实施完毕。自2025年8月5日至11月4日，其通过集中竞价减持3,218,000股，占总股本0.7098%。减持完成后持股比例降至4.9808%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2580781580","title":"11月4日宣泰医药发布公告，股东减持8.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580781580","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580781580?lang=zh_cn&edition=full","pubTime":"2025-11-04 18:01","pubTimestamp":1762250509,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日宣泰医药发布公告《宣泰医药:关于持股5%以上股东减持计划时间届满暨减持股份结果公告》，其股东南京市栖和创业投资合伙企业(有限合伙)于2025年10月23日至2025年11月4日间合计减持8.7万股，占公司目前总股本的0.0192%，变动期间该股股价下跌0.09%，截止11月4日收盘报10.86元。股东增减持详情见下表：根据宣泰医药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400029077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774342984723,"stockEarnings":[{"period":"1week","weight":-0.0995},{"period":"1month","weight":-0.1312},{"period":"3month","weight":-0.1112},{"period":"6month","weight":-0.176},{"period":"1year","weight":-0.1453},{"period":"ytd","weight":-0.0856}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7759人(较上一季度减少3.25%)","perCapita":"58427股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、美沙拉秦肠溶缓释片、马昔腾坦片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}